Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 11Sarcoma 6Neoplasms 6Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Kidney Neoplasms 4Gliosarcoma 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liposarcoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

Cisplatin 27Cetuximab 17Radiotherapy 14Carboplatin 14pembrolizumab 11Paclitaxel 11Drug Therapy 8Radiotherapy, Intensity-Modulated 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7Radiation 6Docetaxel 5130-nm albumin-bound paclitaxel 5Panitumumab 4Chemoradiotherapy 3Capecitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Afatinib 3selinexor 2figitumumab 2Restraint, Physical 2Radiosurgery 2Methotrexate 2Lapatinib 2Everolimus 2Esophagectomy 2Cyclophosphamide 2zalutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Squamous Cell × temsirolimus × Clear all
NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 2 Terminated
13 enrolled 8 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡